Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults-Reference-Cited by-同舟云学术

Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults

Published:2016 Issue:2 Volume:3 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Lindeman Tara A.¹,Duggan Joan M.²,Sahloff Eric G.³

Affiliation:

1. PGY-2 Infectious Diseases Pharmacy Resident, VA St. Louis Healthcare System, Missouri

2. Division of Infectious Diseases, College of Medicine and Life Sciences

3. College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Ohio

Abstract

Abstract This retrospective chart review evaluated changes in serum creatinine and creatinine clearance (CrCl) after initiation of an integrase inhibitor (INSTI)-based regimen as initial treatment in human immunodeficiency virus-infected adults. Serum creatinine and CrCl changes were similar to those seen in clinical trials for INSTIs. No renal-related serious adverse events or discontinuations occurred.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/3/2/ofw053/33604700/ofw053.pdf

Reference8 articles.

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services;Panel on Antiretroviral Guidelines for Adults and Adolescents

2. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial;Lennox;Lancet,2009

3. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from randomized, double-blind, non-inferiority SPRING-2 study;Raffi;Lancet,2013

4. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection;Walmsley;N Engl J Med,2013

5. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomized, double-blind phase 3, non-inferiority trial;DeJesus;Lancet,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies;HIV Medicine;2024-05-17

2. Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa;British Journal of Clinical Pharmacology;2024-02-08

3. Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV;International Journal of STD & AIDS;2022-11-15

4. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults;Medicine;2022-10-21

5. Less common drug interaction and its solution demonstrated on the example of HIV patient from the perspective of clinical practice;Praktické lékárenství;2022-06-22